Daniel Thomas, MD
Interventional Pain Medicine · Athens, GANPI 1871768671
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,528 of the $5,355 with a category attached, or 65.9%. 28 manufacturers reported payments, led by Abbott at 46.6% of the total. Reporting peaked in 2020 at $2,081 and has fallen 80.4% since, to $408 in 2025.
Across 181 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Pacira Pharmaceuticals Incorporated$706
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$521
- Medtronic$205
- SPR Therapeutics, Inc$200
- Boston Scientific$190
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,70432%
- Food & beverage$3,52866%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 66 | $2,495 |
| Pacira Pharmaceuticals Incorporated | 7 | $706 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $521 |
| Medtronic(2 entities) | 6 | $205 |
| SPR Therapeutics, Inc | 2 | $200 |
| Boston Scientific | 10 | $190 |
| Vertos Medical, Inc. | 3 | $170 |
| Nevro Corp. | 6 | $126 |
| Amgen | 8 | $124 |
| Scilex Pharmaceuticals Inc. | 6 | $108 |
| Teva Pharmaceuticals USA, Inc. | 7 | $101 |
| USWM, LLC | 2 | $45 |
| Biogen | 2 | $37 |
| MDD US Operations, LLC | 2 | $35 |
| Stimwave Technologies Incorporated | 3 | $35 |
| Redhill Biopharma Inc. | 2 | $29 |
| Si-bone, Inc. | 2 | $28 |
| Almatica Pharma LLC | 2 | $28 |
| Pfizer | 2 | $27 |
| Vertex | 1 | $22 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| Forte Bio-pharma LLC | 1 | $22 |
| Avanos Medical | 1 | $16 |
| Biotronik NRO, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Radius Health, Inc. | 1 | $12 |
| GRT US Holding, Inc. | 1 | $11 |
| Nalu Medical, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$1,275
- Iovera$618
- SPRINT PNS System$149
- Proclaim IPG$139
- RESTORE$128
- PROCLAIM$123
- mild Device Kit$114
How this compares
$5,355 in reported general payments places this provider in the 55th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,069 | $46,344 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,395 | $45,035 |
| Oxycodone Hcl | 635 | $13,872 |
| Xtampza ErOxycodone Myristate | 20 | $12,554 |
| Fentanyl | 126 | $11,080 |
| LinzessLinaclotide | 17 | $9,902 |
| MovantikNaloxegol Oxalate | 22 | $9,404 |
| Gabapentin | 607 | $9,054 |
| Buprenorphine | 45 | $8,492 |
| OxycontinOxycodone Hcl | 14 | $7,245 |
| ZtlidoLidocaine | 13 | $6,020 |
| Pregabalin | 202 | $4,580 |
| Naloxone Hcl | 63 | $4,313 |
| Tramadol Hcl | 325 | $2,404 |
| Lidocaine | 18 | $2,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $14 | $9,90217 claims |
| Redhill Biopharma Inc.Movantik | $29 | $9,40422 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $108 | $6,02013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Athens
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
- Guensley DelvaWaycross$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.